<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34742667</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5010</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society</Title><ISOAbbreviation>J Cyst Fibros</ISOAbbreviation></Journal><ArticleTitle>Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.</ArticleTitle><Pagination><StartPage>339</StartPage><EndPage>343</EndPage><MedlinePgn>339-343</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcf.2021.10.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1569-1993(21)02104-4</ELocationID><Abstract><AbstractText>Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta) is the newest Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drug approved by the Food and Drug Administration. Post-marketing reports with earlier CFTR modulators suggest these medications can impact mood, and in clinical trials an adverse effect of headache was reported with all currently approved CFTR modulators. However, there are no other documented reports of mental status changes during clinical trials or in post-marketing reports with elexacaftor/tezacaftor/ivacaftor. In this case series, we describe 6 patients who reported "mental fogginess" or other mental status changes shortly after initiation of this drug. The mechanism of this patient-reported side effect is still unclear. All patients noticed a change within the first 3 months of therapy. The management differed in each case, with all four cystic fibrosis (CF) care teams utilizing a patient-centered decision-making approach to address this concern.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Suyeon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Chicago State University College of Pharmacy, 9501 S. King Drive Douglas Hall 206, Chicago, IL 60628, United States. Electronic address: sheo@csu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>University of Utah, Department of Pharmacotherapy, Salt Lake City, UT, 30 South 2000 East Room 4916, Salt Lake City, UT 84112, United States. Electronic address: david.young@hsc.utah.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safirstein</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital of the University of Pennsylvania, Department of Pharmacy, Philadelphia, PA, 3400 Civic Center Boulevard, Philadelphia, PA 19104, United States. Electronic address: julie.safirstein@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourque</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Dartmouth-Hitchcock, Dartmouth-Hitchcock Specialty Pharmacy, Lebanon, NH, 1 Medical Center Drive, Lebanon, NH 03766, United States. Electronic address: Brian.Bourque@hitchcock.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antell</LastName><ForeName>Martine H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>University of Vermont, Department of Pharmacy, Burlington, VT, 111 Colchester Ave, Burlington, VT 05401, United States. Electronic address: Martine.Antell@uvmhealth.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diloreto</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Maine Medical Center, Department of Pharmacy, Portland, ME, 22 Bramhall St., Portland, ME 04102, United States. Electronic address: sdiloreto@mmc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotolo</LastName><ForeName>Shannon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>University of Chicago Medicine, Department of Pharmacy, Chicago, IL, 5841 S Maryland Avenue, MC0010, Chicago, IL 60637, United States. Electronic address: shannon.rotolo@uchospitals.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Cyst Fibros</MedlineTA><NlmUniqueID>101128966</NlmUniqueID><ISSNLinking>1569-1993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000627">Aminophenols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052117">Benzodioxoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065101">Chloride Channel Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000625213">tezacaftor</NameOfSubstance></Chemical><Chemical><RegistryNumber>126880-72-6</RegistryNumber><NameOfSubstance UI="D019005">Cystic Fibrosis Transmembrane Conductance Regulator</NameOfSubstance></Chemical><Chemical><RegistryNumber>1Y740ILL1Z</RegistryNumber><NameOfSubstance UI="C545203">ivacaftor</NameOfSubstance></Chemical><Chemical><RegistryNumber>RRN67GMB0V</RegistryNumber><NameOfSubstance UI="C000629074">elexacaftor</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000711647">long COVID brain fog</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000627" MajorTopicYN="N">Aminophenols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052117" MajorTopicYN="N">Benzodioxoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065101" MajorTopicYN="N">Chloride Channel Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003550" MajorTopicYN="Y">Cystic Fibrosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019005" MajorTopicYN="Y">Cystic Fibrosis Transmembrane Conductance Regulator</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005222" MajorTopicYN="N">Mental Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013001" MajorTopicYN="N">Somatoform Disorders</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cystic fibrosis</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</Keyword><Keyword MajorTopicYN="N">Elexacaftor</Keyword><Keyword MajorTopicYN="N">Memory loss</Keyword><Keyword MajorTopicYN="N">altered mental status</Keyword></KeywordList><CoiStatement>Conflict of interest statement No authors have financial or personal relationships that could inappropriately influence this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>7</Day><Hour>20</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34742667</ArticleId><ArticleId IdType="doi">10.1016/j.jcf.2021.10.002</ArticleId><ArticleId IdType="pii">S1569-1993(21)02104-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>